HomeAbout usHospitalsSearchLogin
Your medical data, safe and secure.
Name
Ponatinib
Description
Ponatinib is a novel Bcr-Abl tyrosine kinase inhibitor that is especially effective against the T315I mutation for the treatment of chronic myeloid leukemia. FDA approved on December 14, 2012.
No brand information found.
